Role of Manual Therapy for Neck Pain and Quality of Life in Head and Neck Cancer Survivors: A Systematic Review

Post-operative Therapeutic Management in an Adult Female With Cystic Hygroma: A Rare Case

Birth abnormalities affecting the lymphatic system include cystic lymphangiomas. They are rare in adults and typically happen in childhood. The cause of adult cystic hygroma (CH), which has a benign nature, is yet unknown. Seventy-five percent of lymphatic malformations have a CH as their primary site of origin in the head and neck area. We describe a 36-year-old female case of cervical cystic lymphangioma who complained of swelling on the left side of her neck for two years. There was no prior history of fever, trauma, weight loss, appetite loss, discharge, or swallowing difficulties. The doctor advised investigations like computed tomography neck, ultrasound sonography neck, etc., and was diagnosed with cystic lymphangioma. Early physiotherapy seems beneficial in preserving shoulder movement and minimizing pain in individuals. Cryotherapy is useful in treating patients with lymphangioma after surgery to reduce pain and swelling. This clinical case study demonstrates how patients with cystic lymphangiomas can benefit from physical treatment and regain their functional independence.

Fisetin, a dietary flavonoid, increases the sensitivity of chemoresistant head and neck carcinoma cells to cisplatin possibly through HSP90AA1/IL-17 pathway

Cisplatin (DDP) resistance is a bottleneck in the treatment of head and neck cancer (HNC), leading to poor prognosis. Fisetin, a dietary flavonoid, has low toxicity and high antitumor activity with unclear mechanisms. We intended to predict the targets of fisetin for reversing DDP-resistance and further verify their expressions and roles. A network pharmacology approach was applied to explore the target genes. The hub genes were screened out and subjected to molecular docking and experimental verification (in vivo and in vitro). Thirty-two genes common to fisetin and DDP-resistance were screened, including three hub genes, namely HSP90AA1, PPIA, and PTPRS. Molecular docking suggested that fisetin and the candidate proteins could bind tightly. HSP90AA1 was identified as the key gene. Administration of fisetin increased the sensitivity of chemoresistant cells (Cal27/DDP and FaDu/DDP) to DDP, accompanied by the downregulation of HSP90AA1 and IL-17. HSP90AA1 silencing increases the sensitivity of DDP-resistant cells to DDP, which was mediated by IL-17. In summary, fisetin might inhibit the chemoresistance of HNC cells to DDP by targeting the HSP90AA1/IL-17 pathway. Several hub genes might be the targets of fisetin for reversing DDP-resistance in HNC cells and might also serve as prognostic factors and therapeutic targets for HNC.